Sun Pharmaceutical Industries Limited

As of June 30, 2026, Sun Pharmaceutical Industries Limited carries a market capitalization of 4.47T, placing it among publicly traded companies globally. Its enterprise value stands at 4.47T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Sun Pharmaceutical Industries Limited's next confirmed earnings release is scheduled for October 30, 2026.

As of June 30, 2026, Sun Pharmaceutical Industries Limited has 2.40B shares outstanding.

As of June 30, 2026, Sun Pharmaceutical Industries Limited trades at a trailing price-to-earnings ratio of 39.75.

As of June 30, 2026, Sun Pharmaceutical Industries Limited trades at an EV/EBITDA multiple of 29.47 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 7.58 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 36.58 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 4.47T versus a market cap of 4.47T, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 21.53M in revenue per employee across its workforce of 27,399.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Sun Pharmaceutical Industries Limited recorded 37.12B in income tax expense. That works out to an effective tax rate of 24.66, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 150.50B, leaving 112.56B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Sun Pharmaceutical Industries Limited's stock has gained approximately 3.14% over the past 52 weeks. The 50-day moving average sits at 1,849.01, while the 200-day moving average is 1,807.76.

Over the twelve months ended June 30, 2026, Sun Pharmaceutical Industries Limited generated 589.98B in revenue and converted that into 112.56B in net income, yielding earnings per share of 47.03. EBITDA reached 151.79B, while operating income came in at 137.43B.

Over the twelve months ended June 30, 2026, Sun Pharmaceutical Industries Limited posted a gross margin of 80.47, reflecting its pricing power and cost economics. The operating margin of 23.29 and net profit margin of 19.08 provide insight into operational efficiency.

Sun Pharmaceutical Industries Limited's most recent stock split took place on July 29, 2013 with a 1:2 split ratio.